American hero targeted by Trump bashes administration: ‘I’m not backing down’

U.S. Sen. Mark Kelly (D-Ariz.) slammed President Donald Trump’s administration after the Pentagon announced it would be ...
Yahoo Finance

Theratechnologies Submits sBLA for Trogarzo® Intramuscular (IM) Method of Administration to FDA

This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, ...
Monthly Prescribing Reference

Intramuscular Administration of HIV Treatment Ibalizumab Compared With IV Infusion

Results were announced from a phase 3 study evaluating an investigational intramuscular (IM) formulation of ibalizumab-uiyk for the treatment of heavily treatment-experienced adults with ...
Medscape

FDA Okays IM Administration for Peginterferon Beta-1a in MS

The US Food and Drug Administration (FDA) has approved intramuscular (IM) administration of peginterferon β-1a (Plegridy, Biogen) for patients with relapsing forms of multiple sclerosis (MS). "The new ...
Slingshot News on MSN

'I'm Not Sure That's Even Possible': Trump Makes Freudian Slip, Admits He Doesn't Believe His Own Administration's Border Statistics During Rally

During his remarks at a rally in July, President Trump admitted that he doesn't believe in his own administration's border ...
Nature

Utility of intramuscular antibiotics for secondary prevention of early onset, asymptomatic ‘suspected’ neonatal sepsis

To evaluate the safety, efficacy and cost–benefit of intramuscular (IM) antibiotics administration in the secondary prevention of suspected neonatal sepsis in asymptomatic term neonates. Retrospective ...
Nasdaq

Biogen Says FDA Approves PLEGRIDY Intramuscular Administration For MS - Quick Facts

(RTTNews) - Biogen Inc. (BIIB) said Monday that the U.S. Food and Drug Administration has approved a new intramuscular (IM) injection route of administration for PLEGRIDY (peginterferon beta-1a) for ...
Nasdaq

Primary endpoint met in COMET-TAIL Phase 3 trial evaluating intramuscular administration of sotrovimab for early treatment of COVID-19

LONDON and SAN FRANCISCO, Nov. 12, 2021 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced headline data from the randomized, ...